Nektar Therapeutics (NKTR) Surges on Positive Trial Results & Price Target Hike

Font: Financial Modeling Prep  • Apr 21, 2026

Nektar Therapeutics (NASDAQ: NKTR) Surges on Positive Clinical Trial Results and Analyst Price Target Hike

Nektar Therapeutics announced positive clinical trial results for its alopecia areata treatment, driving significant stock price appreciation.
Analyst firm Wedbush maintained a "Neutral" rating but raised its price target for Nektar Therapeutics to $95.00 from $70.00, signaling a more positive outlook.
The company is conducting a public offering to raise $250.00 million, providing capital for operations but potentially increasing share count.

Nektar Therapeutics is a clinical-stage biotechnology company. It focuses on developing new treatments for diseases. Recently, the company announced positive results from a trial for its alopecia areata treatment, a condition that causes hair loss. This news caused its stock price to increase significantly.

On April 21, 2026, analyst firm Wedbush Securities maintained its "Neutral" investment rating on Nektar Therapeutics with a hold action. A neutral rating suggests that the analyst expects the biotechnology stock to perform in line with the overall market. It is not a strong recommendation to buy or sell the shares at their current price.

Wedbush also raised its price target for Nektar Therapeutics to $95.00 from a previous target of $70.00. A price target is an analyst's estimate of a stock's future value. This increase indicates a more positive investment outlook on the company's potential, even while the overall rating remains neutral.

At the time of the announcement, Nektar Therapeutics' stock price was $100.35. This is higher than Wedbush's new price target of $95.00. The biotech stock's recent market performance includes a daily gain of 18.25%, reaching a new 52-week high of $109.00. This market surge followed the positive trial results, as highlighted by Barron's.

Nektar Therapeutics has also started a public offering to raise $250.00 million, as reported by PR Newswire. This involves selling new shares of its common stock to the public. Such a capital raise provides the company with cash for its operations but can also increase the total number of shares available, potentially leading to share dilution.